Category Archives: Genetic Medicine

Sarepeta Therapeutics and StrideBio will collaborate to advance novel gene therapies for four genetic neurological disorders, including Rett syndrome, the companies have announced.

Under the agreement, StrideBio, which specializes in viral-based delivery systems for gene therapy, will conduct initial research, development, and manufacturing for the first four gene targets in these neurological disorders: MECP2 (Rett syndrome), SCN1A (Dravet syndrome), UBE3A (Angelman syndrome), and NPC1 (Niemann-Pick).

The main goal of the early development stage is to obtain investigational new drug approvals from the U.S. Food and Drug Administration, which are mandatory to start clinical trials.

In turn, Sarepta, a company focusing on precision genetic medicine, expands its gene therapy pipeline by gaining exclusive licenses on the selected targets. It also gains the possibility to extend licensing to four additional targets (for a total of eight) in neuromuscular and central nervous system diseases.

StrideBio owns aplatform to create adeno-associated viral (AAV) vectors, a class of modified viruses that are used to deliver gene therapy. They are engineered to be harmless (non-infectious) and work to deliver functioning genes directly into specific cells and tissues.

One of the current challenges in gene therapy is that some people carry a natural immunity against AAVs, in the form of neutralizing antibodies that react against these vectors and prevent gene therapies from working. In addition, immune reactions against AAVs can also become toxic for patients. This limits the number of patients who can benefit from AAV-based gene therapies, as carriers of neutralizing antibodies are excluded from gene therapy trials and treatments.

StrideBios platform addresses this problem by creating novel AAV capsids, or protein shells, that enclose the genetic material to be delivered and are able to escape pre-existing neutralizing antibodies.

As such, the platform holds promise for gene therapies to be used in a greater number of patients, the company says.

These new capsids can also be engineered to improve specific delivery of gene therapy to tissues of interest in a particular condition.

Sarepta and StrideBio plan to address re-dosing challenges as well in patients who have received some sort of AAV-based gene therapy.

With our partnership with StrideBio, Sarepta continues to build on its leadership position in gene therapies to treat rare diseases. We are excited to work with StrideBio and access its innovative AAV platform for next-generation capsids, Doug Ingram, Sareptas president and CEO, said in a press release.

Our partnership with StrideBio expands our research portfolio by up to eight new targets and ensures that we gain access to new technology and targets while not distracting Sarepta from its near-term priorities, he added.

Sapan Shah, PhD, StrideBios CEO, said: This partnership will provide significant resources and expertise to enable StrideBios continued rapid expansion of our research and manufacturing platform, as well as accelerate the development of AAV gene therapies for multiple rare disease targets.

We are looking forward to working together with Sarepta to bring novel treatments to patients as quickly as possible, he added.

Sarepta will pay StrideBio $48 million as upfront payment, in addition to future payments for development, regulatory, and commercial milestones for the four programs. StrideBio will also receive royalties on potential worldwide sales.

If the collaboration is expanded to the four additional targets, Sarepta will pay up to $42.5 million along with future milestone payments.

Ana is a molecular biologist with a passion for discovery and communication. As a science writer she looks for connecting the public, in particular patient and healthcare communities, with clear and quality information about the latest medical advances. Ana holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in genetics, molecular biology, and infectious diseases.

Total Posts: 2

Jos is a science news writer with a PhD in Neuroscience from Universidade of Porto, in Portugal. He has also studied Biochemistry at Universidade do Porto and was a postdoctoral associate at Weill Cornell Medicine, in New York, and at The University of Western Ontario in London, Ontario, Canada. His work has ranged from the association of central cardiovascular and pain control to the neurobiological basis of hypertension, and the molecular pathways driving Alzheimers disease.

Read the original post:
Rett Among Disorders Targetted for Gene Therapies in Partnership Deal - Rett Syndrome News

Tulane University neuroscientist Dr. Stacy Drury will launch the Telomere Research Network to establish best practices for measuring telomere length and how it can be used as a sentinel of aging-related disease risk. Photo by Paula Burch-Celentano.

The National Institutes of Health awarded a $2.9 million grant to Tulane University neuroscientist Dr. Stacy Drury to lead a research network that will set methodological standards for studying a part of the chromosome that scientists increasingly recognize as an important biological marker of aging and age-related diseases.

Drury will launch theTelomere Research Network to establish best practices for measuring telomere length in population-based studies. Telomeres are the caps at the end of chromosomes that keep them from shrinking when cells replicate. Shorter telomeres are linked to higher risks for heart disease, obesity, cognitive decline, diabetes, mental illness and poor health outcomes in adulthood.

The network willdefine the extent to which telomere length can be effectively applied as a sentinel of aging-related disease risk and an indicator of environmental and psychosocial stress exposure across the life span, said Drury, the Remigio Gonzalez, MD, Professor of Child Psychiatry at Tulane University School of Medicine. We are charged with bringing together all of the international experts in the field and becoming a central focus for this research across the globe.

There has been an explosion in telomere research within the last decade. But scientists have used different measurement criteria, leading to problems replicating research results in some studies.

As it becomes clearer that it is a very powerful marker, the rigor of the science has to get better, Drury said. Because so many people are studying it in so many different ways, we don't want to dilute the impact by having lots of people using methodology that isnt the best.

The network will define the extent that telomeres can be used as a marker of environmental exposures, psychosocial stress and disease susceptibility. It will also provide a forum for researchers to share samples, research data, study protocols and discussions on best practices for the field.

The network will convene for its first meeting Dec. 5-6 in Washington, D.C. The event will be streamed online athttps://tulane.zoom.us/j/258026269.

Weatherhead Professor of Pharmacology John McLachlan is a co-investigator on the grant. Drury will be working with collaborators at the University of Groningen, University of California at San Francisco, Georgetown University, Pennsylvania State University and Rutgers University.

The NIHs National Institute on Aging and the National Institute of Environmental Health Sciences funded the initiative under grant award No.U24AG066528.

Read more:
NIH taps Tulane neuroscientist to lead effort to standardize research in genetic aging - News from Tulane

Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT): Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The US$8.4b market-cap posted a loss in its most recent financial year of -US$361.9m and a latest trailing-twelve-month loss of -US$620.3m leading to an even wider gap between loss and breakeven. The most pressing concern for investors is SRPTs path to profitability when will it breakeven? Ive put together a brief outline of industry analyst expectations for SRPT, its year of breakeven and its implied growth rate.

See our latest analysis for Sarepta Therapeutics

According to the 22 industry analysts covering SRPT, the consensus is breakeven is near. They expect the company to post a final loss in 2021, before turning a profit of US$676m in 2022. SRPT is therefore projected to breakeven around 3 years from now. What rate will SRPT have to grow year-on-year in order to breakeven on this date? Using a line of best fit, I calculated an average annual growth rate of 68%, which is rather optimistic! If this rate turns out to be too aggressive, SRPT may become profitable much later than analysts predict.

NasdaqGS:SRPT Past and Future Earnings, December 3rd 2019

Im not going to go through company-specific developments for SRPT given that this is a high-level summary, though, bear in mind that by and large a biotech has lumpy cash flows which are contingent on the product type and stage of development the company is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.

One thing I would like to bring into light with SRPT is its relatively high level of debt. Typically, debt shouldnt exceed 40% of your equity, which in SRPTs case is 44%. Note that a higher debt obligation increases the risk in investing in the loss-making company.

This article is not intended to be a comprehensive analysis on SRPT, so if you are interested in understanding the company at a deeper level, take a look at SRPTs company page on Simply Wall St. Ive also put together a list of relevant aspects you should look at:

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

Here is the original post:
Breakeven On The Horizon For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - Yahoo Finance

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for translational research and molecular diagnostic products, today announced the publication of a collaborative study with the Broad Institute of MIT and Harvard entitled A rapid and accurate method to determine antibiotic susceptibilities based on simultaneous detection of genotype and phenotype that demonstrates the potential for the Hyb & Seq technology to transform infectious disease testing. NanoString and the Broad Institute have entered into a non-exclusive license agreement for intellectual property related to pathogen enrichment, highly sensitive pathogen detection and identification, and phenotypic antibiotic susceptibility determination (https://www.nature.com/articles/s41591-019-0650-9).

Current culture-based methods for antibiotic susceptibility testing (AST) are too slow to inform key clinical decisions. While genotypic assays hold promise, they do not reliably predict antibiotic susceptibility. In a study led by Deborah Hung, M.D., Ph.D., and Core Member of the Broad Institute, investigators demonstrate a rapid assay using the Hyb & Seq technology to classify pathogens as antibiotic susceptible or resistant in less than four hours. By coupling machine learning analysis of quantitative early transcriptional responses to antibiotic exposure with simultaneous detection of key genetic resistance determinants, the AST assay demonstrated 94-99% accuracy. The study shows proof-of-concept that an assay for combined genotypic and phenotypic AST through RNA detection can be deployed directly on a positive blood culture bottle with a simple workflow.

Rapid and accurate pathogen identification and antibiotic susceptibility testing are essential to improved patient outcomes, said Brad Gray, president and CEO of NanoString. This research demonstrates that it may be possible to use our Hyb & Seq technology to achieve these objectives in less than four hours.

NanoString has been collaborating with the laboratories of Dr. Hung and Dr. Jongyoon Han, Ph.D., of the Massachusetts Institute of Technology to advance this technology since 2015. The results of this collaboration were first presented at the Association for Molecular Pathology conference in 2018, and subsequently were published in peer-reviewed articles in Scientific Reports and Nature Medicine. Under this non-exclusive licensing agreement with the Broad Institute, NanoString acquired the rights to manufacture and commercialize the Broad Institute technology, to enable pathogen identification and antibiotic susceptibility from diverse samples such as whole blood across a broad number of organisms.

Interested parties can learn more about Hyb & Seq by visiting: https://www.nanostring.com/scientific-content/technology-overview/hyb-seq

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for translational research and molecular diagnostic products. The companys nCounter Analysis System is used in life sciences research and has been cited in more than 2,800 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The companys GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections. The company's technology is also being used in diagnostics. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

For more information, please visit http://www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, Hyb & Seq, nCounter and Prosigna are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the potential of Hyb & Seq technology to enable rapid and accurate antibiotic susceptibility testing. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the potential for Hyb & Seq technology to accurately and quickly determine antibiotic susceptibilities, and the ability of NanoString to successfully commercialize such technology, as well as the other risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. NanoString Technologies disclaims any obligation to update these forward-looking statements.

View post:
Nature Medicine Publication Highlights Use of NanoString's Hyb & Seq Technology to Perform Rapid Genotypic and Phenotypic Antibiotic...

Specific patterns of protein levels in our blood could be used to provide a comprehensive liquid health check that gives a snapshot of health and potentially an indication of the likelihood that we will develop certain diseases or health risk factors in the future, according to research by scientists in the U.S. and U.K. working with SomaLogic. The results of their proof-of-concept study involving more than 16,000 participants, and published in Nature Medicine, showed that while the accuracy of models based on specific protein expression patterns varied, they were all either better predictors than models based on traditional risk factors, or would constitute more convenient and less expensive alternatives to traditional testing.

This proof of concept study demonstrates a new paradigm that measurement of blood proteins can accurately deliver health information that spans across numerous medical specialties and that should be actionable for patients and their healthcare providers, said Peter Ganz, MD, co-leader of this study and the Maurice Eliaser distinguished professor of medicine at UCSF and director of the Center of Excellence in Vascular Research at Zuckerberg San Francisco General Hospital and Trauma Center. I expect that in the future we will look back at this Nature Medicine proteomic study as a critical milestone in personalizing and thus improving the care of our patients. The teams published study is titled, Plasma protein patterns as comprehensive indicators of health.

Preventative medicine programs such as the U.K. National Health Services Health Check and Healthier You programs are aimed at improving individuals health and reducing the risk of developing diseases. While such strategies are inexpensive, cost-effective, and scalable, they could also be made more effective using personalized information about an individuals health and disease risk, the authors suggested. The application of big data in healthcare, assessing and analyzing detailed, large-scale datasets, makes it increasingly feasible to make predictions about health and disease outcomes and enable stratified approaches to prevention and clinical management. Protein scanning represents a potential approach to bridging the gap between the need for practicality and low cost, and the potential for personalized, systemic, and data-driven medicine.

Proteins regulate biological processes and can integrate the effects of genes with the effects of environment, age, existing diseases, and lifestyle behaviors, the authors explained. Our genomes contain about 19,000 genes that code for some 30,000 different proteins. Up to 2,200 of these proteins, including hormones, cytokines, and growth factors, are purposefully secreted into the blood, to orchestrate biological processes in health or in disease. Other proteins enter the blood through leakage from damaged or dead cells. Both secreted and leaked proteins can inform health status and disease risk.

In a proof-of-concept study based on five observational cohorts involving 16,894 participants, the researchers scanned 5,000 proteins in single blood plasma samples taken from each participant, to simultaneously capture the individualized imprints of current health status, the impact of modifiable behaviors, and incident risk of cardiometabolic diseases (diabetes, coronary heart disease, stroke, or heart failure).

To analyze the proteins in each sample the researchers used a technique that harnessed fragments of DNA known as aptamers, which bind to the target protein. In general, only specific fragments will bind to particular proteins. Using existing genetic sequencing technology, the researchers could then search for the aptamers and determine which proteins are present and in what concentrations. In total, the study carried out about 85 million protein measurements in the nearly 17,000 participants.

The researchers analyzed the results using statistical methods and machine learning techniques to develop predictive modelsfor example, that an individual whose blood contains a certain pattern of proteins is at increased risk of developing diabetes. The models covered a number of health states, including levels of liver fat, kidney function and visceral fat, alcohol consumption, physical activity, and smoking behavior, and for risk of developing type 2 diabetes and cardiovascular disease.

The accuracy of the models varied, with some showing high predictive powers, such as for percentage body fat. Other models demonstrated only modest prognostic power, such as that for cardiovascular risk, but even this was still modestly better than traditional risk factors and could also add value in overcoming the incomplete utilization of risk calculation in primary care, the team wrote. Many of the proteins measured linked to a number of health states or conditions. Leptin, for example, modulates appetite and metabolism, and was informative for predictive models of percentage body fat, visceral fat, physical activity, and fitness.

The researchers pointed out that a key feature of the study is that it used information from just one source, a single blood draw, for protein-phenotype models, the authors pointed out. This was a key objective of our health check proof of concept. The team didnt include demographic or known risk factors in their modelsunless absolutely necessary. They also didnt test whether they models could be improved by adding in other features, such as history, laboratory tests, or genetic information. It is possible that these multi-source models could improve absolute models performance, although their inclusion has potential implications for increasing costs and loss of convenience.

One difference between genome sequencing and proteomics approaches is that whereas the genome is fixed, the proteome changes over time, possibly as an individual becomes more obese, less physically active, or smokes, for example. These changes in proteins could be used to track changes in an individuals health status over a lifetime.

Proteins circulating in our blood are a manifestation of our genetic make-up as well as many other factors, such as behaviors or the presence of disease, even if not yet diagnosed, said Claudia Langenberg, M.D., from the MRC Epidemiology Unit at the University of Cambridge. This is one of the reasons why proteins are such good indicators of our current and future health state and have the potential to improve clinical prediction across different and diverse diseases.

While this study shows a proof-of-principle, the researchers acknowledged that there were limitations, and suggested that as technology improves and becomes more affordable, it is feasible that a comprehensive health evaluation using a battery of protein models derived from a single blood sample, could be offered as routine by health services. It is thus conceivable that, with further validation and the potential for expansion of the number of tests, a comprehensive, holistic health evaluation using a battery of protein models derived from a single blood sample could be performed. The next step is to test the applicability of the protein models that we have derived and validated in observational cohorts under research conditions in real-world healthcare systems.

Its remarkable that plasma protein patterns alone can faithfully represent such a wide variety of common and important health issues, and we think that this is just the tip of the iceberg, said study lead Stephen Williams, M.D., chief medical officer at SomaLogic, which is developing its SomaScan Platform and SomaSignal tests for a wide range of human diseases. We have more than a hundred tests in our SomaSignal pipeline and believe that large-scale protein scanning has the potential to become a sole information source for individualized health assessments.

See more here:
Blood Test that Measures Expression of 5,000 Proteins Shows Potential as Disease Screening Tool - Clinical OMICs News

SALT LAKE CITY, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and precision medicine, today announced that multiple studies will be presented at the 2019 San Antonio Breast Cancer Symposium (SABCS) being held Dec. 10-14, 2019 in San Antonio, Tx.

"We are excited to present new data from several studies at SABCS this year, said Nicole Lambert, president of Myriad Oncology. "Our data represents Myriads commitment to advancing precision oncology for people with breast cancer and improving outcomes.

A list of the companys presentations at SABCS is below. Please visit Myriad at booth #113 to learn more about our portfolio of genetic tests for breast cancer. Follow Myriad on Twitter via @myriadgenetics and keep up to date with Symposium news by using the hashtag #SABCS19.

About Myriad myRisk Hereditary CancerThe Myriad myRisk Hereditary Cancer test uses an extensive number of sophisticated technologies and proprietary algorithms to evaluate 35 clinically significant genes associated with eight hereditary cancer sites including: breast, colon, ovarian, endometrial, pancreatic, prostate and gastric cancers and melanoma.

About riskScoreriskScore is a new clinically validated personalized medicine tool that enhances Myriads myRisk Hereditary Cancer test. riskScore helps to further predict a womens lifetime risk of developing breast cancer using clinical risk factors and genetic-markers throughout the genome. The test incorporates data from greater than 80 single nucleotide polymorphisms identified through 20 years of genome wide association studies in breast cancer and was validated in our laboratory to predict breast cancer risk in women of European descent. This data is then combined with a best-in-class family and personal history algorithm, the Tyrer-Cuzick model, to provide every patient with individualized breast cancer risk.

About EndoPredictEndoPredict is a second-generation, prognostic test that aids personalized treatment planning for patients with early-stage breast cancer. EndoPredict has been validated in over 3500 patients with node-negative and node-positive disease and is the leading breast prognostic in Europe. In contrast to first-generation multigene prognostic tests, EndoPredict incorporates a 12-gene molecular score with known prognostic factors tumor size and nodal status. In clinical studies, EndoPredict demonstrated its robust ability to predict recurrence risk across multiple time-periods: 0-5, 5-10, and 5-15 years. EndoPredict provides clinically actionable information to physicians and patients as they consider the use of adjuvant chemotherapy and extended endocrine therapy.

About Myriad GeneticsMyriad Genetics Inc. is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore, Prolaris, Foresight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the Companys data across multiple genetic tests being featured at the 2019 San Antonio Breast Cancer Symposium being held Dec. 10-14, 2019 in San Antonio, Tx.; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Continued here:
Myriad Genetics to Present Multiple Studies on Breast Cancer at the 2019 San Antonio Breast Cancer Symposium - GlobeNewswire